

Technology Advisory Committee A Interests Register

Nivolumab for previously treated unresectable advanced oesophageal cancer [ID1249]

Publication Date: 15/06/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Elizabeth Smith	Clinical Expert	Direct - financial	Compensated for advisory roles or educational lectures by Astellas, Astra Zeneca, BMS, Celgene, Five Prime, Gritstone Oncology, Merck and Servier. Dr Smith also received honorarium for travel to conferences from Astellas, Astra Zeneca, BMS and Servier.	NA	29/02/2020	NA	It was agreed that these declarations would not prevent Dr Smith from providing expert advice to the committee.